Atorvastatin in Pulmonary Arterial Hypertension (APATH) study
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Statins have been shown to both prevent and attenuate pulmonary hypertension in animal models. This study investigates the potential therapeutic benefits of atorvastatin as an affordable treatment for pulmonary hypertension patients. 220 patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH) were randomised, double-blind, to receive atrovastatin 10 mg daily or matching placebo in addition to supportive care. At 6 months, 6-min walk distance decreased by 16.6 m in the atorvastatin group and 14.1 m in the placebo group. The mean placebo-corrected treatment effect was -2.5 m (95% CI: -38–33; p=0.96), based on intention to treat. A small nonsignificant increase in pulmonary vascular resistance and fall in cardiac output was seen in both treatment groups. There was no significant difference in the proportion of patients who improved, remained stable or showed a deterioration in World Health Organization functional class between atorvastatin and placebo treatments. Nine patients died in the atorvastatin group and 11 in the placebo group. Serum cholesterol levels fell significantly on atorvastatin treatment. Discontinuation rates were 23.2% and 26.9% on atorvastatin and placebo, respectively. Atorvastatin 10 mg daily has no beneficial effect on the natural history of PAH or CTEPH over 6 months.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Benza, R. L., Miller, D. P., Gomberg-Maitland, M., Frantz, R. P., Foreman, A. J., Coffey, C. S., Frost, A., Barst, R. J., Badesch, D. B., Elliott, C. G., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.898122 · Cited by 1,547
Cited by
Repurposing of statins via inhalation to treat lung inflammatory conditions
Bradbury, P., Traini, D., Ammit, A. J., Young, P. M., & Ong, H. X. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.06.005 · Cited by 38
Efficacy of Statin Therapy in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis
Rysz-Górzynska, M., Gluba-Brzózka, A., Sahebkar, A., Serban, M.-C., Mikhailidis, D. P., Ursoniu, S., Toth, P. P., Bittner, V., Watts, G. F., Lip, G. Y. H., et al. (2016) · Scientific Reports · doi:10.1038/srep30060 · Cited by 33
A systematic review and meta-analysis of trials using statins in pulmonary arterial hypertension
Anand, V., Garg, S., Duval, S., & Thenappan, T. (2016) · Pulmonary Circulation · doi:10.1086/687304 · Cited by 25
Metadata
- Authors
- Zeng, W.-J., Xiong, C.-M., Zhao, L., Shan, G.-L., Liu, Z.-H., Xue, F., Gu, Q., Ni, X.-H., Zhao, Z.-H., Cheng, X.-S., Wilkins, M. R., & He, J.-G.
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2012-02-23
- Volume
- 40
- Issue
- 1
- Pages
- 67-74
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W1949536786
- Cited by
- 62
- References
- 2
- FWCI
- 3.79
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Atorvastatin in Pulmonary Arterial Hypertension (APATH) study. https://app.cochat.ai/papers/10.1183/09031936.00149011
- The paper
- Zeng, W.-J., Xiong, C.-M., Zhao, L., Shan, G.-L., Liu, Z.-H., Xue, F., Gu, Q., Ni, X.-H., Zhao, Z.-H., Cheng, X.-S., Wilkins, M. R., & He, J.-G. (2012). Atorvastatin in Pulmonary Arterial Hypertension (APATH) study. European Respiratory Journal. https://doi.org/10.1183/09031936.00149011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.